Elizabeth Tarka

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome

Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White et al. · JAMA · 2014 · 456 citations

Medicine, Cardiology, Pharmacology +17

Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease

Emil Hagström, Claes Held, Ralph Stewart et al. · Clinical Chemistry · 2016 · 129 citations · Full text

Medicine, Cardiology, Clinical Cardiology +16

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

Harvey D. White, Claes Held, Ralph Stewart et al. · American Heart Journal · 2010 · 126 citations

Medicine, Cardiology, Pharmacology +17

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White et al. · American Heart Journal · 2011 · 91 citations

Medicine, Cardiology, Clinical Sciences +17

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: An open‐label, safety, efficacy, and pharmacokinetic study

Guy Young, L Boshkov, Janice E. Sullivan et al. · Pediatric Blood & Cancer · 2010 · 76 citations

Medicine, Hematology, Pediatrics +17